Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Publisher Correction: The long tail of oncogenic drivers in prostate cancer.

Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM; PCF/SU2C International Prostate Cancer Dream Team, Schultz N, Van Allen EM.

Nat Genet. 2019 May 31. doi: 10.1038/s41588-019-0451-6. [Epub ahead of print]

PMID:
31152158
2.

Genomic correlates of clinical outcome in advanced prostate cancer.

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, De Sarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW, Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL.

Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. doi: 10.1073/pnas.1902651116. Epub 2019 May 6.

3.

A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).

Mazzu YZ, Armenia J, Chakraborty G, Yoshikawa Y, Coggins SA, Nandakumar S, Gerke TA, Pomerantz MM, Qiu X, Zhao H, Atiq M, Khan N, Komura K, Lee GM, Fine SW, Bell C, O'Connor E, Long HW, Freedman ML, Kim B, Kantoff PW.

Clin Cancer Res. 2019 Apr 17. doi: 10.1158/1078-0432.CCR-18-4046. [Epub ahead of print]

PMID:
30996073
4.

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.

Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI.

JAMA Oncol. 2018 Dec 27. doi: 10.1001/jamaoncol.2018.5801. [Epub ahead of print]

PMID:
30589920
5.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Nov 1;128(11):5185. doi: 10.1172/JCI125184. Epub 2018 Nov 1. No abstract available.

6.

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.

Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, Shia J, Hechtman JF, Kundra R, El Dika I, Do RK, Sun Y, Kingham TP, D'Angelica MI, Berger MF, Hyman DM, Jarnagin W, Klimstra DS, Janjigian YY, Solit DB, Schultz N, Abou-Alfa GK.

Clin Cancer Res. 2019 Apr 1;25(7):2116-2126. doi: 10.1158/1078-0432.CCR-18-2293. Epub 2018 Oct 29.

PMID:
30373752
7.

Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.

Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, Viswanathan K, Vosoughi A, Blattner M, Stopsack KH, Zadra G, Penney KL, Mosquera JM, Tyekucheva S, Mucci LA, Barbieri C, Loda M.

Mol Cancer Res. 2019 Feb;17(2):446-456. doi: 10.1158/1541-7786.MCR-18-0440. Epub 2018 Oct 17.

PMID:
30333152
8.

Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.

Pietzak EJ, Zabor EC, Bagrodia A, Armenia J, Hu W, Zehir A, Funt S, Audenet F, Barron D, Maamouri N, Li Q, Teo MY, Arcila ME, Berger MF, Schultz N, Dalbagni G, Herr HW, Bajorin DF, Rosenberg JE, Al-Ahmadie H, Bochner BH, Solit DB, Iyer G.

Eur Urol. 2019 Feb;75(2):231-239. doi: 10.1016/j.eururo.2018.09.002. Epub 2018 Oct 2.

PMID:
30290956
9.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Oct 1;128(10):4441-4453. doi: 10.1172/JCI121924. Epub 2018 Sep 4. Erratum in: J Clin Invest. 2018 Nov 1;128(11):5185.

10.

Genome doubling shapes the evolution and prognosis of advanced cancers.

Bielski CM, Zehir A, Penson AV, Donoghue MTA, Chatila W, Armenia J, Chang MT, Schram AM, Jonsson P, Bandlamudi C, Razavi P, Iyer G, Robson ME, Stadler ZK, Schultz N, Baselga J, Solit DB, Hyman DM, Berger MF, Taylor BS.

Nat Genet. 2018 Aug;50(8):1189-1195. doi: 10.1038/s41588-018-0165-1. Epub 2018 Jul 16.

11.

Integrated Molecular Characterization of Testicular Germ Cell Tumors.

Shen H, Shih J, Hollern DP, Wang L, Bowlby R, Tickoo SK, Thorsson V, Mungall AJ, Newton Y, Hegde AM, Armenia J, Sánchez-Vega F, Pluta J, Pyle LC, Mehra R, Reuter VE, Godoy G, Jones J, Shelley CS, Feldman DR, Vidal DO, Lessel D, Kulis T, Cárcano FM, Leraas KM, Lichtenberg TM, Brooks D, Cherniack AD, Cho J, Heiman DI, Kasaian K, Liu M, Noble MS, Xi L, Zhang H, Zhou W, ZenKlusen JC, Hutter CM, Felau I, Zhang J, Schultz N, Getz G, Meyerson M, Stuart JM; Cancer Genome Atlas Research Network, Akbani R, Wheeler DA, Laird PW, Nathanson KL, Cortessis VK, Hoadley KA.

Cell Rep. 2018 Jun 12;23(11):3392-3406. doi: 10.1016/j.celrep.2018.05.039.

12.

ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.

Komura K, Yoshikawa Y, Shimamura T, Chakraborty G, Gerke TA, Hinohara K, Chadalavada K, Jeong SH, Armenia J, Du SY, Mazzu YZ, Taniguchi K, Ibuki N, Meyer CA, Nanjangud GJ, Inamoto T, Lee GM, Mucci LA, Azuma H, Sweeney CJ, Kantoff PW.

J Clin Invest. 2018 Jul 2;128(7):2979-2995. doi: 10.1172/JCI96769. Epub 2018 Jun 4.

13.

Unifying cancer and normal RNA sequencing data from different sources.

Wang Q, Armenia J, Zhang C, Penson AV, Reznik E, Zhang L, Minet T, Ochoa A, Gross BE, Iacobuzio-Donahue CA, Betel D, Taylor BS, Gao J, Schultz N.

Sci Data. 2018 Apr 17;5:180061. doi: 10.1038/sdata.2018.61.

14.

Oncogenic Signaling Pathways in The Cancer Genome Atlas.

Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M; Cancer Genome Atlas Research Network, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N.

Cell. 2018 Apr 5;173(2):321-337.e10. doi: 10.1016/j.cell.2018.03.035.

15.

Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas.

Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, Sander C, Cherniack AD, Mina M, Ciriello G, Schultz N; Cancer Genome Atlas Research Network, Sanchez Y, Greene CS.

Cell Rep. 2018 Apr 3;23(1):172-180.e3. doi: 10.1016/j.celrep.2018.03.046.

16.

The long tail of oncogenic drivers in prostate cancer.

Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM; PCF/SU2C International Prostate Cancer Dream Team, Schultz N, Van Allen EM.

Nat Genet. 2018 May;50(5):645-651. doi: 10.1038/s41588-018-0078-z. Epub 2018 Apr 2. Erratum in: Nat Genet. 2019 May 31;:.

17.

Expression of lncRNA MIR222HG co-transcribed from the miR-221/222 gene promoter facilitates the development of castration-resistant prostate cancer.

Sun T, Du SY, Armenia J, Qu F, Fan J, Wang X, Fei T, Komura K, Liu SX, Lee GM, Kantoff PW.

Oncogenesis. 2018 Mar 13;7(3):30. doi: 10.1038/s41389-018-0039-5.

18.

Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer.

Shah N, Wang P, Wongvipat J, Karthaus WR, Abida W, Armenia J, Rockowitz S, Drier Y, Bernstein BE, Long HW, Freedman ML, Arora VK, Zheng D, Sawyers CL.

Elife. 2017 Sep 11;6. pii: e27861. doi: 10.7554/eLife.27861.

19.

Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.

Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S, McLaughlin B, Curtis K, Hyman DM, Durack JC, Solomon SB, Arcila ME, Zehir A, Syed A, Gao J, Chakravarty D, Vargas HA, Robson ME, Joseph V, Offit K, Donoghue MTA, Abeshouse AA, Kundra R, Heins ZJ, Penson AV, Harris C, Taylor BS, Ladanyi M, Mandelker D, Zhang L, Reuter VE, Kantoff PW, Solit DB, Berger MF, Sawyers CL, Schultz N, Scher HI.

JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00029. Epub 2017 May 31.

20.

CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation.

Dall'Acqua A, Sonego M, Pellizzari I, Pellarin I, Canzonieri V, D'Andrea S, Benevol S, Sorio R, Giorda G, Califano D, Bagnoli M, Militello L, Mezzanzanica D, Chiappetta G, Armenia J, Belletti B, Schiappacassi M, Baldassarre G.

EMBO Mol Med. 2017 Oct;9(10):1415-1433. doi: 10.15252/emmm.201607012.

21.

ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.

Bose R, Karthaus WR, Armenia J, Abida W, Iaquinta PJ, Zhang Z, Wongvipat J, Wasmuth EV, Shah N, Sullivan PS, Doran MG, Wang P, Patruno A, Zhao Y; International SU2C/PCF Prostate Cancer Dream Team, Zheng D, Schultz N, Sawyers CL.

Nature. 2017 Jun 29;546(7660):671-675. doi: 10.1038/nature22820. Epub 2017 Jun 14.

22.

An Integrated Approach Identifies Mediators of Local Recurrence in Head and Neck Squamous Carcinoma.

Citron F, Armenia J, Franchin G, Polesel J, Talamini R, D'Andrea S, Sulfaro S, Croce CM, Klement W, Otasek D, Pastrello C, Tokar T, Jurisica I, French D, Bomben R, Vaccher E, Serraino D, Belletti B, Vecchione A, Barzan L, Baldassarre G.

Clin Cancer Res. 2017 Jul 15;23(14):3769-3780. doi: 10.1158/1078-0432.CCR-16-2814. Epub 2017 Feb 7.

23.

Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism.

Sood A, Miller AM, Brogi E, Sui Y, Armenia J, McDonough E, Santamaria-Pang A, Carlin S, Stamper A, Campos C, Pang Z, Li Q, Port E, Graeber TG, Schultz N, Ginty F, Larson SM, Mellinghoff IK.

JCI Insight. 2016 May 5;1(6). pii: 87030. doi: 10.1172/jci.insight.87030.

24.

Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.

Dalin MG, Desrichard A, Katabi N, Makarov V, Walsh LA, Lee KW, Wang Q, Armenia J, West L, Dogan S, Wang L, Ramaswami D, Ho AL, Ganly I, Solit DB, Berger MF, Schultz ND, Reis-Filho JS, Chan TA, Morris LG.

Clin Cancer Res. 2016 Sep 15;22(18):4623-33. doi: 10.1158/1078-0432.CCR-16-0637. Epub 2016 Apr 21.

25.

Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway.

Fabris L, Berton S, Citron F, D'Andrea S, Segatto I, Nicoloso MS, Massarut S, Armenia J, Zafarana G, Rossi S, Ivan C, Perin T, Vaidya JS, Avanzo M, Roncadin M, Schiappacassi M, Bristow RG, Calin G, Baldassarre G, Belletti B.

Oncogene. 2016 Sep 15;35(37):4914-26. doi: 10.1038/onc.2016.23. Epub 2016 Feb 15.

26.

p27kip1 controls H-Ras/MAPK activation and cell cycle entry via modulation of MT stability.

Fabris L, Berton S, Pellizzari I, Segatto I, D'Andrea S, Armenia J, Bomben R, Schiappacassi M, Gattei V, Philips MR, Vecchione A, Belletti B, Baldassarre G.

Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):13916-21. doi: 10.1073/pnas.1508514112. Epub 2015 Oct 28.

27.

Physical and chemical injuries to eyes and eyelids.

Pargament JM, Armenia J, Nerad JA.

Clin Dermatol. 2015 Mar-Apr;33(2):234-7. doi: 10.1016/j.clindermatol.2014.10.015. Epub 2015 Jan 17. Review.

PMID:
25704943
28.

Contact inhibition modulates intracellular levels of miR-223 in a p27kip1-dependent manner.

Armenia J, Fabris L, Lovat F, Berton S, Segatto I, D'Andrea S, Ivan C, Cascione L, Calin GA, Croce CM, Colombatti A, Vecchione A, Belletti B, Baldassarre G.

Oncotarget. 2014 Mar 15;5(5):1185-97.

29.

p70S6 kinase mediates breast cancer cell survival in response to surgical wound fluid stimulation.

Segatto I, Berton S, Sonego M, Massarut S, Fabris L, Armenia J, Mileto M, Colombatti A, Vecchione A, Baldassarre G, Belletti B.

Mol Oncol. 2014 May;8(3):766-80. doi: 10.1016/j.molonc.2014.02.006. Epub 2014 Mar 12.

30.

Inhibition of breast cancer local relapse by targeting p70S6 kinase activity.

Segatto I, Berton S, Sonego M, Massarut S, D'Andrea S, Perin T, Fabris L, Armenia J, Rampioni G, Lovisa S, Schiappacassi M, Colombatti A, Bristow RG, Vecchione A, Baldassarre G, Belletti B.

J Mol Cell Biol. 2013 Dec;5(6):428-31. doi: 10.1093/jmcb/mjt027. Epub 2013 Jul 29. No abstract available.

PMID:
23899505
31.

Comparing the rate of regression after conductive keratoplasty with or without prior laser-assisted in situ keratomileusis or photorefractive keratectomy.

Moshirfar M, Anderson E, Hsu M, Armenia JM, Mifflin MD.

Middle East Afr J Ophthalmol. 2012 Oct;19(4):377-81. doi: 10.4103/0974-9233.102743.

32.

The incidence of central serous chorioretinopathy after photorefractive keratectomy and laser in situ keratomileusis.

Moshirfar M, Hsu M, Schulman J, Armenia J, Sikder S, Hartnett ME.

J Ophthalmol. 2012;2012:904215. doi: 10.1155/2012/904215. Epub 2012 Feb 12.

33.

Abducens paralysis repaired with muscle transposition and intraoperative botulinum toxin.

Armenia JV, Sigal MB.

Ann Ophthalmol. 1987 Nov;19(11):416-8, 422.

PMID:
3426040
34.

Effectiveness of programmed learning as homework for culturally deprived high school students.

Armenia J.

Psychol Rep. 1967 Jun;20(3):785-6. No abstract available.

PMID:
6042484
35.

Cataract extraction with Kelman cryostylet.

Jones WY, Wahlig AF, Golesic S, Armenia JV.

N Y State J Med. 1967 May 1;67(9):1170-3. No abstract available.

PMID:
5232542
36.

MEASUREMENT OF RENAL PLASMA FLOW BY IODOPYRACET I-131.

ELWOOD CM, ARMENIA J, ORMAN D, MORRIS A, SIGMAN EM.

JAMA. 1965 Sep 6;193:771-4. No abstract available.

PMID:
14329974
37.

EFFICACY OF COLISTIMETHATE SODIUM IN TREATMENT OF PSEUDOMONAS INFECTION.

JONES WY, ARMENIA JV.

Am J Ophthalmol. 1963 Nov;56:758-61. No abstract available.

PMID:
14077180
38.

Supplemental Content

Loading ...
Support Center